β-tubulin与紫杉醇类耐药在肺癌中的研究进展

Research advance on β-tubulin related chemoresistance to paclitaxel drugs in lung cancer

目的:总结国内外关于β-tubulin与紫杉醇类耐药在肺癌治疗中的基础与临床研究进展。方法:应用Medline及CNKI期刊全文数据库系统,以"肺癌"、"微管蛋白(tubulin)"、"紫杉醇"、"化疗"为关键词,检索2010-2011年前相关文献。共检索到英文文献371篇,中文文献82篇。纳入标准:1)微管蛋白分子研究;2)肺癌细胞系与tubulin及紫杉醇类化疗耐药研究;3)与tubulin及紫杉醇类化疗耐药相关肺癌临床试验研究。结果:基础与临床研究均揭示β-tubulinⅢ与紫杉醇类耐药存在明确的负相关性,其可通过突变、过表达、多药耐药等机制诱发紫杉醇类化疗耐药,β-tu-bulinⅢ高表达预示肺癌患者预后不佳。结论:β-tubulinⅢ与肺癌含紫杉醇类化疗方案耐药相关,对其抑制或逆转为肺癌提高化疗效果提供了重要新思路。

OBJECTIVE： To summarize the domestic and abroad articles related to the tubulin family and paclitaxel in chemoresistance in lung cancer. METHODS：Lung cancer, tubulin, paclitaxel, chemotherapy were searched as key words by Medline and CNKI series full-text database retrieval system from 2010 to 2011. Totally 371 English articles and 82 Chinese articles were obtained. Choice criteria： 1） microstructure of the tubulin family; 2） chemoresistance in lung cancer cell lines related to tubulin family and paclitaxel; 3） clinical trials on lung cancer patients related to tubulin family and paclitaxel. RESULTS： Both fundamental experiments and clinical trials revealed that β-tubulin III expression was significantly correla ted with chemoresistance to paclitaxel. Gene mutation and over-expression and multidrug resistance were most possible mechanisms of the chemoresistance. β-tubulin III over-expression in lung cancer tumor cells correlated to worse prognosis. CONCLUSIONS： According to the close relationship between 13-tubulin III and the chemoresistance to paclitaxel drugs, reversing or inhibiting tubulin may be a new way to improve the result of the chemotherapy containing paclitaxel drugs.